Trial Profile

Prospective Randomized Open, Blinded Endpoint (PROBE) Study of AMDX-2011P as a Retinal Tracer in Subjects With Neurodegenerative Diseases Associated With Amyloidogenic Proteinopathy

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 23 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

21 Feb 2023 According to Amydis media release, this study is funded in part by a $3 million commercialization readiness pilot grant from the National Institute of Aging at National Institutes of Health (NIH) is evaluating the safety, tolerability, pharmacokinetics and activity of AMDX-2011P.
31 Jan 2023 Planned End Date changed from 28 Feb 2023 to 1 Dec 2023.
31 Jan 2023 Planned primary completion date changed from 30 Nov 2022 to 1 Sep 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com